These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 35722665

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J, Bai X, Feng X, Ni J, Beretov J, Graham P, Li Y.
    BMC Cancer; 2019 Jun 24; 19(1):618. PubMed ID: 31234823
    [Abstract] [Full Text] [Related]

  • 4. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S, Mai Z, Liu C, Xu L, Xia C.
    Phytomedicine; 2023 Mar 24; 111():154669. PubMed ID: 36681055
    [Abstract] [Full Text] [Related]

  • 5. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells In Vitro and In Vivo through Inhibiting the PI3K/AKT/mTOR/NF-κB Signaling Pathway.
    Yang H, Li H, Lu S, Shan S, Guo Y.
    Biomed Res Int; 2022 Mar 24; 2022():5739909. PubMed ID: 35281608
    [Abstract] [Full Text] [Related]

  • 6. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
    Bai H, Li H, Li W, Gui T, Yang J, Cao D, Shen K.
    Oncotarget; 2015 Sep 22; 6(28):25520-32. PubMed ID: 26267321
    [Abstract] [Full Text] [Related]

  • 7. Suppression of PI3K/Akt/mTOR Signaling Pathway and Antioxidant System and Reversal of Cancer Cells Resistance to Cisplatin under the Effect of Curcumin.
    Kalinina EV, Hasan AAS, Tatarskiy VV, Volodina YL, Petrova АS, Novichkova MD, Zhdanov DD, Nurmuradov NK, Chernov NN, Shtil AA.
    Bull Exp Biol Med; 2022 Jul 22; 173(3):371-375. PubMed ID: 35854021
    [Abstract] [Full Text] [Related]

  • 8. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M, Bamodu OA, Huang WC, Zucha MA, Lin YK, Wu ATH, Huang CC, Lee WH, Yuan CC, Hsiao M, Deng L, Tzeng YM, Yeh CT.
    Toxicol Appl Pharmacol; 2017 Jun 15; 325():48-60. PubMed ID: 28408137
    [Abstract] [Full Text] [Related]

  • 9. Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway.
    El-Kott AF, Shati AA, Al-Kahtani MA, Alqahtani S.
    Anal Cell Pathol (Amst); 2019 Jun 15; 2019():9627810. PubMed ID: 31360627
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G, Zhang Q.
    Oncotarget; 2015 Sep 22; 6(28):25281-94. PubMed ID: 26325371
    [Abstract] [Full Text] [Related]

  • 12. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY, Zhao ZQ, Bai R, Zhao W, Wang YX, Xue HQ, Sun L, Sun C, Feng W, Guo SB.
    Oncol Rep; 2020 Apr 22; 43(4):1169-1186. PubMed ID: 32323781
    [Abstract] [Full Text] [Related]

  • 13. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J, Liu L, Ling Y, Zheng J.
    J Biochem Mol Toxicol; 2021 Sep 22; 35(9):e22853. PubMed ID: 34309113
    [Abstract] [Full Text] [Related]

  • 14. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
    Zhang X, Qin T, Zhu Z, Hong F, Xu Y, Zhang X, Xu X, Ma A.
    Am J Med Sci; 2020 Feb 22; 359(2):123-129. PubMed ID: 32039764
    [Abstract] [Full Text] [Related]

  • 15. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L, Sun YH, An R, Cheng RJ, Li N, Zheng JH.
    Kaohsiung J Med Sci; 2023 Aug 22; 39(8):779-788. PubMed ID: 37218642
    [Abstract] [Full Text] [Related]

  • 16. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK, Manavathi B.
    Cell Oncol (Dordr); 2017 Apr 22; 40(2):133-144. PubMed ID: 28039608
    [Abstract] [Full Text] [Related]

  • 17. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O.
    Clin Cancer Res; 2011 Apr 15; 17(8):2373-84. PubMed ID: 21372221
    [Abstract] [Full Text] [Related]

  • 18. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J, Feng L, Tian C, Tang YL, Tang Y, Hu FQ.
    Eur Rev Med Pharmacol Sci; 2018 Dec 15; 22(23):8135-8144. PubMed ID: 30556851
    [Abstract] [Full Text] [Related]

  • 19. Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT).
    Thaklaewphan P, Wikan N, Potikanond S, Nimlamool W.
    Biomolecules; 2024 Sep 09; 14(9):. PubMed ID: 39334906
    [Abstract] [Full Text] [Related]

  • 20. The effects of REG4 expression on chemoresistance of ovarian cancer.
    Xiang LW, Xue H, Ha MW, Yu DY, Xiao LJ, Zheng HC.
    J Obstet Gynaecol; 2022 Oct 09; 42(7):3149-3157. PubMed ID: 35929918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.